Users Discontinuing Slimming Medications Regain Weight Far More Rapidly Than Those on Conventional Diets

Fresh analysis reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt traditional diet and exercise regimens.

Research printed in a major medical journal demonstrates that while overweight individuals can lose a large proportion of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.

"Users using such drugs must be cognizant of the risk of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.

That rate of regain means a return to starting weight within about one and a half years.

Comparing Approaches

The analysis, which examined 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.

Scientists point out that people who shed pounds through dieting usually see a less rapid weight regain—around 0.1 kg a month—after stopping.

Understanding the Fast Rebound

Nutrition scientists suggest the mechanism of the injections accounts for the heightened rebound.

These medications mimic a natural hormone called GLP-1, which controls appetite.

"Long-term administration of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this medication means hunger is uncontrolled, making overeating far more likely."

A Chronic Issue?

Health authorities recommend the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.

Professionals argue that, due to the significant potential of weight regain, the therapy should be considered life-long.

This perspective is supported by pharmaceutical companies, who note that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like hypertension.

Patient Accounts

Users who have stopped the jabs report a intense resurgence of appetite.

"I experienced a switch activating and you become extremely hungry," recalled an individual.

This challenge is exacerbated if patients have not developed permanent dietary or behavioural modifications during therapy.

Widespread Adoption

Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is higher among females compared to males.
• The 40s and 50s age group shows the highest usage rates.
• Many obtain the drugs through private prescriptions rather than public health services.

In conclusion, experts caution that while the jabs are potent agents for weight loss, they are not a magic cure and maintained weight loss relies on combined lifestyle changes.